<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="672">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152407</url>
  </required_header>
  <id_info>
    <org_study_id>3020_ILS-MIRORU20</org_study_id>
    <secondary_id>ID RCB 2020-A02883-36</secondary_id>
    <nct_id>NCT05152407</nct_id>
  </id_info>
  <brief_title>MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis</brief_title>
  <official_title>MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis A Single-center Clinical Study in Two Phases: First Phase: Randomized Double-blind Clinical Interventional Study Versus Placebo in Split Face or Split Skull Second Phase: Open-label Observational Clinical Study on the Entire Face or Skull</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NAOS Institute of Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NAOS Institute of Life Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate effectiveness of a serum containing 0.3% of MRB, a&#xD;
      cosmetic active ingredient, against actinic lentigo and actinic keratosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skin aging is an extremely complex multifactorial process that disrupts the functions and&#xD;
      structure of epidermal and dermal cells and extracellular matrix components and has multiple&#xD;
      causes including extrinsic phenomena (UV radiation, exposure to pollution, etc.).&#xD;
&#xD;
      It has important effects on the skin and is particularly apparent on the face. Indeed,&#xD;
      sunlight, in particular ultraviolet light, is an important factor that contributes to&#xD;
      cutaneous photoaging by inducing the photo-chronic generation of reactive oxygen species&#xD;
      (ROS). Although skin has its own antioxidant system against ROS, these antioxidant defenses&#xD;
      are not fully effective during sun exposure and weaken over time. Photoaging of the skin is&#xD;
      characterized by the development of pigmentary disorders, such as actinic lentigos (AL), as&#xD;
      well as benign skin tumors such as actinic keratosis (AK), both of which are target&#xD;
      pathologies for this study.&#xD;
&#xD;
      AL usually occur in the elderly. They are usually benign but can cause aesthetic problems.&#xD;
      They are commonly seen on the hands but can appear on all areas of the body, especially on&#xD;
      sun-exposed areas such as the face, back, arms, feet, shoulders and skull. There are&#xD;
      different treatment approaches, including physical therapy such as laser therapy, pulsed&#xD;
      light, chemical peeling, bleaching and cryotherapy or topical therapy such as hydroquinone&#xD;
      (HQ). Although topical therapies are generally more time consuming compared to physical&#xD;
      therapies, patients can control their own treatment and side effects can be decreased.&#xD;
&#xD;
      AK is a very common skin lesion caused by chronic sun damage that typically measure less than&#xD;
      1 cm in diameter. KA is considered a premalignant epithelial skin lesion that may progress to&#xD;
      squamous cell carcinoma. For this reason, all KA should be treated and clinical follow-up is&#xD;
      recommended. The goals of treatment are: (i) to clinically eradicate obvious and subclinical&#xD;
      lesions, (ii) to prevent their progression to EC, and (iii) to reduce the number of relapses&#xD;
      and consequently increase the quality of life of patients.&#xD;
&#xD;
      Medical treatment with antioxidant properties/actions that would allow the reduction of&#xD;
      damaged cells seems to play a role in both the prevention and treatment of AL and KA (Nashan&#xD;
      et al., 2013).&#xD;
&#xD;
      In addition, a paper published in early 2020 highlighted a major role for carbonylation in&#xD;
      the progression of this type of skin lesion (Tramutola et al., 2020). Based on these&#xD;
      elements, we hypothesize that our cosmetic active ingredient - MRB - which has antioxidant&#xD;
      activity and a specific and original chaperone effect giving it a strong capacity to fight&#xD;
      against protein carbonylation- will be effective in the treatment of photo-induced signs of&#xD;
      aging: keratoses and actinic lentigo, by a mechanism that acts on the oxidative stress&#xD;
      pathway and the maintenance of cellular proteostasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate MRB 0.3% serum effectiveness on 2 early clinical markers of photoinduced cutaneous aging: actinic lentigo and actinic keratosis</measure>
    <time_frame>After 6 months of treatment</time_frame>
    <description>The primary endpoint will be the decrease at 6 months from baseline in the overall score determined by the sum of the total number of actinic lentigos and actinic keratoses on each hemi-face, one receiving MRB 0.3% serum and the other a placebo serum. For men with baldness, the evaluation could be performed on each hemi-skull and/or each hemi-face.&#xD;
The counting of the two types of lesions will be done by simple dermatological examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate 0.3% MRB serum effectiveness versus a placebo serum at inclusion, 1, 3 and 6 months of treatment on the evolution of actinic lentigos on each hemi- face and/or skull</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Assessment at inclusion (T0), after 1 month, 3 months and 6 months of treatment of the number of actinic lentigos on each hemiface and/or hemiskull (in men with baldness) treated with MRB serum 0.3% and placebo serum respectively. The counting of the lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate 0.3% MRB serum effectiveness versus a placebo serum at inclusion, 1, 3 and 6 months of treatment on the evolution actinic keratoses on each hemi-face/skull</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Assessment at inclusion (T0), after 1 month, 3 months and 6 months of treatment of the number of actinic keratoses on each hemi-facial and/or hemi-cranial area (in men with baldness) treated with MRB 0.3% serum and placebo serum respectively. The counting of the lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate 0.3% MRB serum effectiveness versus a placebo serum at inclusion, 1, 3 and 6 months of treatment on the grade of actinic keratoses on each hemi-face/skull</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Assessment at inclusion (T0), after 1 month, 3 months and 6 months of treatment of the grade of actinic keratosis defined by the AK-FAS (Actinic Keratosis Field Assessment Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on the whole face and/or skull the effect of a MRB 0.3% serum on actinic lentigos and actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on the whole face and/or skull of the overall score determined by the sum of the total number of actinic lentigos and actinic keratoses on the whole face and/or skull. The counting of the two types of lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on the whole face and/or skull the effect of a MRB 0.3% serum on actinic lentigos</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on the whole face and/or skull of the number of actinic lentigos.&#xD;
The counting of the lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on the whole face and/or skull the effect of a MRB 0.3% serum on actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on the whole face and/or skull of the number of actinic keratoses.&#xD;
The counting of the lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on the whole face and/or skull the effect of a MRB 0.3% serum on the grade of actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on the whole face and/or skull of the AK-FAS grade of actinic keratosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on each hemi-face and/or skull the effect of a MRB 0.3% serum on actinic lentigos</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on each hemi-face and/or hemi-skull (in men with baldness) of the number of actinic lentigos.&#xD;
The counting of the lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on each hemi-face and/or skull the effect of a MRB 0.3% serum on actinic lentigos and actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on each hemi-face and/or hemi-skull (in men with baldness) of the overall score determined by the sum of the total number of actinic lentigos and actinic keratoses on each hemi-face.&#xD;
The counting of the two types of lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on each hemi-face and/or skull the effect of a MRB 0.3% serum on actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on each hemi-face and/or hemi-skull (in men with baldness) of the number of actinic keratoses.&#xD;
The counting of the two types of lesions will be done by simple dermatological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in the long term, at 9 and 12 months, on each hemi-face and/or skull (in men with baldness) the effect of a MRB 0.3% serum on the grade of actinic keratoses</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Assessment after 9 months and 12 months on each hemi-face and/or hemi-skull (in men with baldness) of the AK-FAS grade of actinic keratosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate at each visit, the tolerance of MRB 0.3% serum versus a placebo serum</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Tolerance assessed at each visit.&#xD;
It will be assessed by the investigator during the visits using a 5-point scale (0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Extreme) evaluating the following parameters:&#xD;
Erythema&#xD;
Desquamation&#xD;
Burning&#xD;
Pruritus&#xD;
Stretch A global score of tolerance will be calculated by the sum of the 5 parameters. The global score can vary between 0 and 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate at 6 and 12 months from inclusion, the evolution of a lesioned area and an area of normal skin by confocal microscopy on each hemi-face/skull of 10 volunteer subjects.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Confocal microscopy of a lesioned area and an area of normal skin: a study of the cells of the epidermis (keratinocytes), the dermis (fibroblasts) and the cellular infiltrate will be performed on a predefined area of each hemi-face/skull of 3 x3 cm at T0 (Inclusion) by Confocal Microscopy with a High Resolution Ultrasound (LC-OCT) and will be repeated at 6 and 12 months in 10 subjects The area will include at least one KA lesion, one lentigo lesion, and the peri-lesional healthy skin area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the satisfaction of the subjects at 6 months (in hemi-face and/or skull), at 9 and 12 months (for the whole face and/or skull and in hemi-face and/or skull) regarding the use of a MRB 0.3 % serum</measure>
    <time_frame>6, 9 and 12 months</time_frame>
    <description>Subject satisfaction will be evaluated at 6 months on each hemi-face and/or hemi-skull and at 9 and 12 months on the whole face and/or skull and in hemi-face and/or skull via a satisfaction questionnaire (abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the satisfaction of the subjects regardind galenic at 6 months (in hemi-face and/or skull), at 9 and 12 months (for the whole face and/or skull and in hemi-face and/or skull) regarding the use of the applied serums</measure>
    <time_frame>6, 9 and 12 months</time_frame>
    <description>Subject satisfaction will be evaluated at 6 months on each hemi-face and/or hemi-skull and at 9 and 12 months on the whole face and/or skull and in hemi-face and/or skull via a questionnaire on the galenic quality of the applied products (texture, ease of application, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the satisfaction of the investigator at 6, 9 and 12 months regarding the products used</measure>
    <time_frame>6, 9 and 12 months</time_frame>
    <description>The investigator's satisfaction with the products will be evaluated at 6 months on each hemi-face and/or hemi-skull and at 9 and 12 months on the whole face and/or skull on a 5-point scale:&#xD;
= Very good effectiveness&#xD;
= Good effectiveness&#xD;
= Average effectiveness&#xD;
= Poor effectiveness&#xD;
= Not effective at all</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate compliance</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Product compliance will be assessed during the visits by weighing the tubes of product collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Actinic Keratosis</condition>
  <condition>Actinic Lentigo</condition>
  <arm_group>
    <arm_group_label>Active serum on right</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right hemi face or skull will receive active serum (containing 0.3% MRB) / Left hemi face or skull will receive placebo serum for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active serum on left</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left hemi face or skull will receive active serum (containing 0.3% MRB) / Right hemi face or skull will receive placebo serum for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)</intervention_name>
    <description>Serums will be topically applied twice a day (mornings and evenings).</description>
    <arm_group_label>Active serum on left</arm_group_label>
    <arm_group_label>Active serum on right</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum of 5 actinic lentigos and 3 actinic keratoses of grade 1 or 2 on each&#xD;
             hemi-face of the face and/or hemi-cranium (in men with baldness)&#xD;
&#xD;
          -  Phototype I to III&#xD;
&#xD;
          -  Patients with free, informed, written consent to participate in the study.&#xD;
&#xD;
          -  Women unable to conceive or women of childbearing potential with a negative urine&#xD;
             pregnancy test and using contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with less than 5 actinic lentigos or less than 3 actinic keratoses of grade 1&#xD;
             or 2 on each hemiface of the face and/or skull (for men with baldness)&#xD;
&#xD;
          -  Phototype IV to VI&#xD;
&#xD;
          -  Immunocompromised subject&#xD;
&#xD;
          -  Subjects with a history of skin carcinoma in the treated areas&#xD;
&#xD;
          -  Subjects using another active treatment for actinic keratoses or lentigos (or having&#xD;
             used one in the past 3 months)&#xD;
&#xD;
          -  Subjects unable to understand the information (due to language or psychiatric reasons)&#xD;
&#xD;
          -  Subjects without social insurance&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Breastfeeding women&#xD;
&#xD;
          -  Women of childbearing age without contraception&#xD;
&#xD;
          -  Subjects under legal protection measures&#xD;
&#xD;
          -  Subjects unable to express their consent&#xD;
&#xD;
          -  Subjects under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Nashan D, Meiss F, MÃ¼ller M. Therapeutic strategies for actinic keratoses--a systematic review. Eur J Dermatol. 2013 Jan-Feb;23(1):14-32. doi: 10.1684/ejd.2013.1923. Review.</citation>
    <PMID>23477760</PMID>
  </reference>
  <reference>
    <citation>Tramutola A, Falcucci S, Brocco U, Triani F, Lanzillotta C, Donati M, Panetta C, Luzi F, Iavarone F, Vincenzoni F, Castagnola M, Perluigi M, Di Domenico F, Marco F. Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression. Cancers (Basel). 2020 Jan 1;12(1). pii: E110. doi: 10.3390/cancers12010110.</citation>
    <PMID>31906275</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NAOS Institute of Life Science</investigator_affiliation>
    <investigator_full_name>JULIE TISSERAND</investigator_full_name>
    <investigator_title>PhD, Project manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

